ABEO
Abeona Therapeutics Inc. NASDAQ Listed Sep 19, 1980$5.78
Mkt Cap $329.7M
52w Low $4.00
50.3% of range
52w High $7.54
50d MA $5.03
200d MA $5.41
P/E (TTM)
4.0x
EV/EBITDA
-2.6x
P/B
1.8x
Debt/Equity
0.2x
ROE
44.7%
P/FCF
-3.3x
RSI (14)
—
ATR (14)
—
Beta
1.21
50d MA
$5.03
200d MA
$5.41
Avg Volume
1.2M
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
1330 Avenue of the Americas · Cleveland, NY 10019 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | AMC | -0.35 | -0.34 | +2.9% | 4.76 | -1.9% | -4.4% | -4.6% | -6.5% | -7.1% | -9.0% | — |
| Nov 12, 2025 | AMC | -0.27 | -0.10 | +63.0% | 4.94 | -0.8% | -8.3% | -9.9% | -8.7% | -9.3% | -15.0% | — |
| Aug 14, 2025 | AMC | -0.39 | 1.71 | +538.5% | 7.23 | +1.7% | -1.4% | -4.4% | -5.4% | -3.2% | -1.7% | — |
| May 15, 2025 | AMC | -0.35 | -0.24 | +31.4% | 5.79 | -0.5% | +5.4% | +7.6% | +10.9% | +11.4% | +13.6% | — |
| Mar 20, 2025 | AMC | -0.43 | -0.24 | +44.2% | 5.14 | -0.8% | +0.2% | -0.4% | -2.7% | -2.9% | -1.9% | — |
| Nov 14, 2024 | AMC | -0.38 | -0.31 | +18.4% | 5.95 | +0.0% | -1.5% | -1.5% | -1.0% | -3.4% | -2.7% | — |
| Aug 12, 2024 | AMC | -0.33 | -0.75 | -127.3% | 4.95 | +0.8% | +0.6% | +0.0% | +1.0% | +1.0% | +5.7% | — |
| May 15, 2024 | AMC | -0.47 | -0.53 | -12.8% | 4.71 | +2.5% | -2.3% | -6.6% | -5.5% | -8.5% | -8.9% | — |
| Mar 18, 2024 | AMC | -0.51 | -0.64 | -25.5% | 6.99 | +0.1% | +8.3% | +7.7% | +7.7% | +8.9% | +5.9% | — |
| Nov 13, 2023 | AMC | -0.53 | -0.48 | +9.4% | 4.50 | +5.1% | -5.6% | -7.8% | -6.2% | -6.9% | -6.2% | — |
| Aug 8, 2023 | AMC | -0.66 | -0.44 | +33.3% | 2.98 | +0.3% | +0.7% | +0.3% | +0.3% | +4.7% | +15.8% | — |
| May 11, 2023 | AMC | -0.58 | -0.54 | +6.9% | 2.97 | -0.3% | +0.0% | +3.7% | +2.0% | -0.3% | +0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.55 | $4.50 | -1.1% | -0.2% | -2.2% | -2.9% | -4.8% | -2.9% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.16 | $5.24 | +1.6% | -0.4% | -2.9% | -3.9% | -7.8% | -4.1% |
| Oct 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.36 | $5.47 | +2.1% | +0.9% | -0.2% | +3.2% | +2.1% | +0.4% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.13 | $7.11 | -0.3% | -3.1% | -4.1% | -1.8% | -0.3% | +1.4% |
| Aug 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.23 | $7.35 | +1.7% | -1.4% | -4.4% | -5.4% | -3.2% | -1.7% |
| Jul 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.95 | $6.01 | +1.0% | +5.2% | +11.4% | +10.8% | +13.4% | +9.6% |
| Jul 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.74 | $5.71 | -0.5% | +3.1% | +3.7% | +9.1% | +15.5% | +14.8% |
| May 16 | Stifel | Maintains | Buy → Buy | — | $5.79 | $5.76 | -0.5% | +5.4% | +7.6% | +10.9% | +11.4% | +13.6% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.30 | $5.39 | +1.7% | +23.8% | +29.6% | +23.8% | +20.8% | +8.7% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.15 | $5.19 | +0.8% | -0.6% | -2.9% | -3.1% | -2.1% | -3.5% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.85 | $5.83 | -0.3% | +0.2% | -0.5% | -1.2% | -6.0% | -8.9% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.98 | $6.06 | +1.3% | -0.7% | +0.8% | +7.2% | +6.9% | +6.0% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.36 | $6.32 | -0.6% | +0.8% | -1.7% | -5.0% | -2.4% | -1.3% |
| Oct 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.39 | $6.78 | +6.1% | +2.8% | -0.5% | +0.3% | -2.2% | -5.5% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.98 | $5.05 | +1.4% | -0.6% | +0.4% | +0.4% | +5.0% | +3.0% |
| Jul 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.19 | $5.20 | +0.2% | +6.2% | +3.9% | +2.9% | +4.4% | -2.9% |
| May 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.71 | $4.83 | +2.5% | -2.3% | -6.6% | -5.5% | -8.5% | -8.9% |
| Apr 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.36 | $3.81 | -48.2% | -53.7% | -56.9% | -56.7% | -55.7% | -53.3% |
| Aug 24 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.13 | $4.16 | +0.7% | -4.6% | -4.8% | -1.7% | -0.5% | +5.1% |
| Jul 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.95 | $3.98 | +0.8% | +1.0% | -1.8% | +1.3% | -1.3% | -4.1% |
| Nov 14 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $4.39 | $4.41 | +0.5% | -5.5% | -8.0% | -10.5% | -9.6% | -8.0% |
| Nov 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.67 | $3.84 | +4.6% | +3.8% | +12.0% | +14.2% | +19.6% | +13.1% |
| Aug 11 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $4.16 | $3.97 | -4.6% | +12.0% | +6.5% | +11.8% | +14.7% | +10.6% |
| Nov 30 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $16.25 | $16.50 | +1.5% | +6.2% | -7.7% | -6.2% | -12.3% | -9.2% |
| Nov 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.25 | $20.50 | +12.3% | -11.0% | -5.5% | -17.8% | -16.4% | -21.9% |
| Jul 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.00 | $32.00 | +0.0% | -3.9% | -1.6% | +5.5% | +3.1% | +2.3% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.75 | $35.00 | +0.7% | +1.4% | +18.7% | +16.5% | +9.4% | +12.2% |
| Nov 11 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $28.75 | $31.00 | +7.8% | +13.0% | +5.2% | +11.3% | +12.2% | +11.3% |
| Nov 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $26.75 | $26.50 | -0.9% | +7.5% | +21.5% | +13.1% | +19.6% | +20.6% |
| May 8 | RBC Capital | Maintains | Outperform → Outperform | — | $58.25 | $58.75 | +0.9% | +15.5% | +39.1% | +30.0% | +40.3% | +37.8% |
| Mar 18 | RBC Capital | Maintains | Outperform → Outperform | — | $51.00 | $49.50 | -2.9% | -16.7% | -12.7% | +4.4% | -4.4% | +1.5% |
| Feb 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $62.75 | $65.00 | +3.6% | +16.7% | +25.9% | +26.3% | +23.1% | +26.3% |
| Aug 15 | Maxim Group | Downgrade | Buy → Hold | — | $60.75 | $57.25 | -5.8% | -10.7% | -9.5% | -8.2% | -9.9% | -9.5% |
| Aug 12 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $57.25 | $53.75 | -6.1% | -0.4% | +4.4% | +6.1% | -5.2% | -3.9% |
| Jul 26 | Mizuho | Downgrade | Buy → Neutral | — | $81.25 | $78.00 | -4.0% | -2.2% | -7.7% | -8.3% | -20.3% | -22.5% |
| Nov 13 | Citigroup | Maintains | Buy → Buy | — | $192.75 | $192.75 | +0.0% | -0.5% | -2.7% | +4.4% | +7.0% | -1.6% |
| Oct 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $483.75 | $485.00 | +0.3% | -9.3% | -16.8% | -13.7% | -7.5% | -9.6% |
| Sep 29 | Maxim Group | Maintains | Buy → Buy | — | $143.50 | $153.75 | +7.1% | +3.0% | +4.5% | +7.1% | +4.7% | +16.6% |
No insider trades available.
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis from this incomplete filing excerpt. Please provide the full 8-K summary or the specific compensation details (such as executive pay changes, equity grants, or severance agreements) to enable proper stock impact assessment.
Apr 7
8-K
Unknown — 8-K Filing
Minor bylaw clarifications without substantive governance changes were adopted, indicating routine corporate housekeeping that poses no material risk or opportunity for shareholders.
Mar 20
8-K
Unknown — 8-K Filing
ABEO's 2025 results emphasis on ZEVASKYN patient experience suggests commercial execution focus, indicating management confidence in the product's market penetration and potential revenue sustainability for investors.
Mar 17
8-K
Abeona Therapeutics Inc. -- 8-K Filing
Abeona Therapeutics commenced commercial launch of its FDA-approved gene therapy ZEVASKYN in Q4 2024, treating the first patient with recessive dystrophic epidermolysis bullosa despite facility shutdown constraints.
Mar 9
Data updated apr 24, 2026 10:13am
· Source: massive.com